US and UK Secure Zero-Tariff Pact on Prescription Drugs.
Britain and America have reached a landmark bilateral deal that will keep no import taxes on UK pharmaceutical shipments entering the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has pledged to increase spending on medicines through the public health system. This pledge secures that duties on these crucial products will remain at nothing for a timeframe of 36 months.
This agreement is in response to recent warnings to significantly raise import taxes on branded pharmaceutical imports, with potential rates mentioned as high as one hundred percent.
"This deal between the Britain strengthens the worldwide climate for new treatments and brings much-needed fairness to transatlantic pharmaceutical trade," a statement noted.
Economic Significance
Drugs represent one of the the United Kingdom's largest export categories to the United States, which is clearly the biggest market for major companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period to the end of last September, the UK sold pharmaceutical products worth over eleven billion pounds to the US. This figure represented a significant portion of total UK exports in that period.
"This agreement safeguards work, stimulates capital expenditure and sets the stage for the UK to emerge as a worldwide center for biotech and pharma," a government official remarked.
Key UK Commitments
The agreement includes several key commitments from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a aim to double total NHS spending on drugs from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The amount drug companies must return to the NHS to prevent overspending will be limited at 15%. In the past, refunds were more than 20%.
Broader Context
This agreement follows a long-running dispute between the sector and the ministers over drug pricing and approval rates.
The disagreement were exacerbated by claims that US patients were paying significantly more for the same drugs than consumers in the UK and Europe.
In recent months, several significant drug company projects in the UK have been halted or cancelled, while substantial investments have been directed toward US facilities.
The Science Minister stated that the NHS needed to invest a greater share on treatments, noting that its spending on drugs had declined as a proportion of its overall budget over the previous ten-year period.
